JP2018507860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507860A5 JP2018507860A5 JP2017544759A JP2017544759A JP2018507860A5 JP 2018507860 A5 JP2018507860 A5 JP 2018507860A5 JP 2017544759 A JP2017544759 A JP 2017544759A JP 2017544759 A JP2017544759 A JP 2017544759A JP 2018507860 A5 JP2018507860 A5 JP 2018507860A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- binding domain
- seq
- protein
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562121406P | 2015-02-26 | 2015-02-26 | |
| US62/121,406 | 2015-02-26 | ||
| PCT/US2016/019401 WO2016138164A1 (en) | 2015-02-26 | 2016-02-24 | A vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific t-cell responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018507860A JP2018507860A (ja) | 2018-03-22 |
| JP2018507860A5 true JP2018507860A5 (enExample) | 2018-12-20 |
Family
ID=56789742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544759A Pending JP2018507860A (ja) | 2015-02-26 | 2016-02-24 | 抗原特異的ｔ細胞反応を誘発するための、免疫原性タンパク質及びアジュバントの組み合わせを含むワクチン組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9775898B2 (enExample) |
| EP (1) | EP3261667A4 (enExample) |
| JP (1) | JP2018507860A (enExample) |
| KR (1) | KR20170105107A (enExample) |
| CN (1) | CN107249629A (enExample) |
| BR (1) | BR112017018017A2 (enExample) |
| IL (1) | IL254110A0 (enExample) |
| RU (1) | RU2017129818A (enExample) |
| TW (1) | TWI674269B (enExample) |
| WO (1) | WO2016138164A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10058606B2 (en) * | 2016-09-19 | 2018-08-28 | Thevax Genetics Vaccine Co., Ltd. | Hepatitis B therapeutic vaccines |
| WO2019133647A1 (en) * | 2017-12-29 | 2019-07-04 | Thevax Genetics Vaccine Co., Ltd. | Combination of a fusion protein vaccine with anti-ox40 antibody for use in eliciting antigen-specific immune responses |
| CN113527511A (zh) * | 2018-09-19 | 2021-10-22 | 天康生物股份有限公司 | 融合蛋白及其制备方法、应用、表达系统和疫苗 |
| CN109663126A (zh) * | 2019-03-01 | 2019-04-23 | 龙阔（苏州）生物工程有限公司 | 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗 |
| TWI763065B (zh) * | 2019-10-04 | 2022-05-01 | 瑞寶基因股份有限公司 | 重組融合蛋白及免疫原組合物 |
| AU2020403296B2 (en) * | 2019-12-13 | 2025-03-06 | Grand Theravac Life Science (Nanjing) Co., Ltd. | Immunostimulatory composition and use thereof |
| KR102898622B1 (ko) * | 2020-04-10 | 2025-12-12 | 악스톤 바이오사이언시스 코퍼레이션 | Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법 |
| CN115956086A (zh) * | 2020-05-06 | 2023-04-11 | 萨摩亚商柏沛生医股份有限公司 | 用于针对癌症及传染病的免疫疗法的融合蛋白 |
| CN111548395A (zh) * | 2020-05-25 | 2020-08-18 | 中国农业科学院兰州兽医研究所 | 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用 |
| CN112626073B (zh) * | 2020-10-26 | 2021-06-15 | 中国科学院昆明动物研究所 | 一种对PRRSV具有特异性免疫刺激作用的CpG-ODN及其应用 |
| CN119912535A (zh) * | 2021-12-28 | 2025-05-02 | 成都迈科康生物科技有限公司 | 一种hpv抗原及其相关产品 |
| CN114835822B (zh) * | 2022-04-22 | 2022-11-04 | 浙江洪晟生物科技股份有限公司 | 猪瘟病毒的多聚体疫苗及其制备方法 |
| WO2025180443A1 (en) * | 2024-02-29 | 2025-09-04 | Immunadd Inc. | Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2138997C (en) * | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| US5712149A (en) * | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| EP1104306B1 (en) * | 1998-08-10 | 2006-01-11 | Antigenics Inc. | Compositions of cpg and saponin adjuvants and methods of use thereof |
| WO2004087754A1 (en) * | 2003-04-03 | 2004-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof |
| HRP20050660A2 (en) * | 2003-01-29 | 2006-02-28 | Pfizer Products Inc. | Canine vaccines against bordetella bronchiseptica |
| US20060217298A1 (en) | 2003-02-04 | 2006-09-28 | Srivastava Pramod K | Immunogenic cd91 ligand-antigenic molecule complexes and fusion proteins |
| KR20090071598A (ko) * | 2006-09-18 | 2009-07-01 | 랩터 파마슈티컬 인코포레이티드 | 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료 |
| EP2078726A1 (en) * | 2008-01-09 | 2009-07-15 | Vision 7 GmbH | Secretable HIV entry inhibitory peptides for therapy of HIV infection |
| US20090203884A1 (en) * | 2008-01-31 | 2009-08-13 | Healthbanks Biotech Co., Ltd. | Chimeric hiv fusion proteins as vaccines |
| MX2011002267A (es) | 2008-08-28 | 2011-03-30 | Glaxosmithkline Biolog Sa | Vacuna. |
| EP2416798B1 (en) * | 2009-04-10 | 2017-09-20 | The Johns Hopkins University | Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines |
| EP2942061A3 (en) | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
| PL391627A1 (pl) * | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| ES2829819T3 (es) * | 2010-08-26 | 2021-06-02 | Toray Industries | Composición inmunogénica |
| US9339536B2 (en) * | 2012-12-05 | 2016-05-17 | Thevax Genetics Vaccine Co., Ltd. | Fusion proteins for use as immunogenic enhancers for inducing antigen-specific T cell responses |
| CA2917192A1 (en) | 2013-07-03 | 2015-01-08 | Synglyco, Inc. | Synthetic oligosaccharides for p. aeruginosa vaccine |
| US20150037374A1 (en) * | 2013-07-31 | 2015-02-05 | Csl Limited | Anti-tumor compositions and uses thereof |
| US10058606B2 (en) * | 2016-09-19 | 2018-08-28 | Thevax Genetics Vaccine Co., Ltd. | Hepatitis B therapeutic vaccines |
-
2016
- 2016-02-24 CN CN201680011623.6A patent/CN107249629A/zh active Pending
- 2016-02-24 US US15/052,713 patent/US9775898B2/en not_active Expired - Fee Related
- 2016-02-24 BR BR112017018017A patent/BR112017018017A2/pt not_active IP Right Cessation
- 2016-02-24 EP EP16756299.0A patent/EP3261667A4/en not_active Withdrawn
- 2016-02-24 KR KR1020177023587A patent/KR20170105107A/ko not_active Ceased
- 2016-02-24 JP JP2017544759A patent/JP2018507860A/ja active Pending
- 2016-02-24 RU RU2017129818A patent/RU2017129818A/ru not_active Application Discontinuation
- 2016-02-24 WO PCT/US2016/019401 patent/WO2016138164A1/en not_active Ceased
- 2016-02-25 TW TW105105741A patent/TWI674269B/zh active
-
2017
- 2017-08-23 IL IL254110A patent/IL254110A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017129818A (ru) | Композиция вакцины, содержащая иммуногенный белок и комбинированные адъюванты, для применения в стимулировании антигенспецифичных т-клеточных ответов | |
| EP2928491B1 (en) | Fusion proteins for use as immunogenic enhancers for inducing antigen-specific t cell responses | |
| JP2016199557A5 (enExample) | ||
| CN114685626B (zh) | Cmv的修饰病毒样颗粒 | |
| JP2016510983A5 (enExample) | ||
| JP2015509707A5 (enExample) | ||
| JP2014530003A5 (enExample) | ||
| JP2013526849A5 (enExample) | ||
| JP2015212284A5 (enExample) | ||
| JP2021502807A5 (enExample) | ||
| IL274130B1 (en) | HIV–1 vaccine immunogens with novel scaffolds | |
| CN107847575A (zh) | 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物 | |
| JP2016520534A5 (enExample) | ||
| JP2018501258A5 (enExample) | ||
| Shen et al. | Self-adjuvanting lipoimmunogens for therapeutic HPV vaccine development: potential clinical impact | |
| RU2007147938A (ru) | Конъюгаты антигенов и их применение | |
| JP2025509352A5 (enExample) | ||
| ES3030310T1 (en) | Sars-cov-2 subunit vaccine | |
| CU24751B1 (es) | Antígeno recombinante para la inducción de respuesta inmune contra el virus zika | |
| TH114418A (th) | วัคซีน | |
| NZ751943B2 (en) | Hepatitis c virus immunogenic compositions and methods of use thereof |